Ariad Announces Positive CHMP Opinion On Continued Availability Of Iclusig

(RTTNews) - Ariad Pharmaceuticals Inc (ARIA), Friday annoucned the adoption of a positive opinion by the Committee for Human Medicinal Products or CHMP of the European Medicines Agency, on the continued availability of Iclusig or ponatinib in the EU for use in patients in its authorized indications. Post the review of its updated clinical-trial data on Iclusig, the CHMP made a series of recommendations on measures to help minimize the risk of occlusive vascular events in patients taking Iclusigm which were approved in July.

"The conclusions reached by the CHMP, which were announced today, confirm a positive benefit-risk assessment for Iclusig after considering the most recent safety information. We expect that this will provide helpful guidance for patients and healthcare professionals as they consider the treatment options."